Irvin Y. Ho

TL;DR: An in-depth study of the B cell response to the pandemic 2009 H1N1 vaccine over consecutive years found that people with low titers of preexisting antibodies were more likely to generate a broadly reactive response that targets the more conserved hemagglutinin (HA) stalk region, whereas those with higher levels of preeXisting antibodies responded by targeting the more variable HA head.

TL;DR: The broadly cross-reactive non-neutralizing antibodies generated in this study were protective through Fc-mediated effector cell recruitment and provide a better understanding of the human monoclonal antibody response to influenza in the context of vaccines.

TL;DR: It is demonstrated that 3 of 83 H3 HA-reactive monoclonal antibodies generated by individuals that had previously undergone influenza A virus vaccination were able to neutralize H7N9 viruses and protect mice against homologous challenge.

TL;DR: Various refinements and dramatically reduce the time required to produce recombinant antibodies are demonstrated and significantly increase single-cell antibody expression efficiency and are easily integrated into established and novel pipelines.

TL;DR: These results suggest that these vaccine formulations are similarly immunogenic but differ in the preferences of the elicited antibodies toward the receptor-binding domain on the HA head.